Education
About Us
Working with TipRanks
Follow Us
Acumen Pharmaceuticals (ABOS)
NASDAQ:ABOS
Earnings Data
Report Date
Aug 18, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.53Last Year’s EPS
-0.34Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 13, 2025
|% Change Since: 1.90%
|Next Earnings Date:Aug 18, 2025
Earnings Call Sentiment|Positive
The earnings call for Acumen Pharmaceuticals demonstrates significant progress and innovation in their Alzheimer’s treatment development, particularly with the rapid enrollment and innovative biomarker use in their ALTITUDE-AD study, as well as promising results in subcutaneous administration. Despite increased R&D expenses and operating losses, the company's strong financial position and strategic advancements indicate a generally positive outlook.Company Guidance
During the Acumen Pharmaceuticals Q1 2025 conference call, the company provided guidance on several key metrics and developments. Acumen completed enrollment of their Phase 2 study, ALTITUDE-AD, with 542 participants in just 10 months, significantly faster than expected. This study aims to evaluate the efficacy and safety of Sabirnetug, their next-generation treatment for early Alzheimer's disease, with topline results anticipated in late 2026. Financially, Acumen reported $197.9 million in cash and marketable securities as of March 31, 2025, projecting this to support operations into early 2027. R&D expenses for the quarter were $25.3 million, primarily driven by ALTITUDE-AD trial costs, while G&A expenses remained steady at $5.1 million. This resulted in a loss from operations of $30.4 million and a net loss of $28.8 million for the quarter. The company also highlighted their innovative use of fluid biomarkers, particularly plasma p-tau 217, which significantly improved screening efficiency, reducing negative PET scans from 60% to 19%.Rapid Enrollment in ALTITUDE-AD Phase 2 Study
Completed enrollment of the 542-participant ALTITUDE-AD Phase 2 study in roughly 10 months, much faster than expected, attributed to the interest in Sabirnetug’s therapeutic potential and innovative participant screening methods.
Innovative Use of Plasma Biomarkers
Used plasma phospho-tau 217 screening to improve enrollment efficiency in ALTITUDE-AD, resulting in 81% of screened individuals testing positive on amyloid PET, compared to 40% in a previous study.
Presentations at Major Alzheimer's Conferences
Presented at ADPD and AAN conferences, highlighting innovative methods in Alzheimer’s drug development, including insights into synaptic biomarkers and A-beta oligomer selective assays.
Progress in Subcutaneous Administration
Completed a Phase 1 study comparing subcutaneous and intravenous administration of Sabirnetug, showing it was well-tolerated with systemic exposure supporting continued development.
Strong Financial Position
Held $197.9 million in cash and marketable securities, expected to support clinical and operational activities into early 2027.
ABOS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ABOS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2025 | $1.05 | $1.05 | 0.00% |
Mar 27, 2025 | $1.16 | $1.23 | +6.03% |
Nov 12, 2024 | $3.22 | $2.68 | -16.77% |
Aug 13, 2024 | $2.56 | $2.77 | +8.20% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Acumen Pharmaceuticals (ABOS) report earnings?
Acumen Pharmaceuticals (ABOS) is schdueled to report earning on Aug 18, 2025, TBA Not Confirmed.
What is Acumen Pharmaceuticals (ABOS) earnings time?
Acumen Pharmaceuticals (ABOS) earnings time is at Aug 18, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ABOS EPS forecast?
ABOS EPS forecast for the fiscal quarter 2025 (Q2) is -0.53.